Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China

被引：0
|
作者：
Huahua Zhang
Yandong Zhang
Chaonan Huang
Jiangfeng Wang
机构：
[1] Fuyang Hospital of Traditional Chinese Medicine,Department of Pharmacy
[2] Fuyang Hospital of Traditional Chinese Medicine,Department of Gynaecology
[3] Ipharmacare Ltd.,Department of Pharmaceutical Services
来源：
Clinical Drug Investigation | 2021年 / 41卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：569 / 577
页数：8
相关论文
共 50 条
  • [1] Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China
    Zhang, Huahua
    Zhang, Yandong
    Huang, Chaonan
    Wang, Jiangfeng
    CLINICAL DRUG INVESTIGATION, 2021, 41 (06) : 569 - 577
  • [2] Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
    Yang, Jiangping
    Han, Jiaqi
    Zhang, Yalan
    Muhetaer, Muhelisa
    Chen, Nianyong
    Yan, Xi
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [3] Cost-effectiveness analysis of trastuzumab emtansine for second-line treatment of HER2+advanced breast cancer in Singapore
    Wong, Wei Han Melvin
    Ng, Raymond
    Aziz, Mohamed Ismail Abdul
    Ong, Benjamin Shao-Kiat
    Ng, Kwong
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025,
  • [4] Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland
    Paulissen, Jeroen H. J.
    Seddik, Ahmed H. H.
    Dunton, Kyle J. J.
    Livings, Christopher J. J.
    van Hulst, Marinus
    Postma, Maarten J. J.
    de Jong, Lisa A. A.
    Freriks, Roel D. D.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2024, 25 (04): : 689 - 699
  • [5] Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
    Fonseca Magalhaes Filho, Marcos Aurelio
    Aguiar, Pedro Nazareth, Jr.
    Mascarenhas Neves, Milena Brachmans
    Lopes, Gilberto de Lima, Jr.
    del Giglio, Auro
    EINSTEIN-SAO PAULO, 2022, 20 : eGS6655
  • [6] Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer
    Guan, X.
    Li, H-C.
    Chen, Q-J.
    Hua, B.
    Li, J-J.
    Ma, F.
    Wang, Y-S.
    Xu, H.
    Liu, C.
    Yang, Q.
    Ma, A-X.
    ANNALS OF ONCOLOGY, 2021, 32 : S45 - S45
  • [7] HER2-positive metastatic Breast Cancer Trastuzumab Emtansine: First Choice for the Second Line
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (11) : 744 - 744
  • [8] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
  • [9] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS PERTUZUMAB WITH TRASTUZUMAB FOR CHINESE PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER
    Guan, X.
    Li, H. C.
    Xia, Y.
    Yang, Q.
    Ma, A. X.
    VALUE IN HEALTH, 2022, 25 (07) : S372 - S372
  • [10] Cost-effectiveness of trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer (ABC)
    Quang Anh Le
    Bae, Yuna
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345